Long-term cognitive effects of menopausal hormone therapy: Findings from the KEEPS Continuation Study
PLOS Medicine · 21.11.2024 · 21 (11) · e1004435
DOI: 10.1371/journal.pmed.1004435 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS Medicine, online erschienen am 21.11.2024. Verfasst von Carey E Gleason und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Wisconsin, Madison, Wisconsin, United States of America. Hauptthemen laut MEDLINE: Cognition, Estrogen Replacement Therapy, Estrogens, Conjugated (USP). Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: NIA NIH HHS, NCRR NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Background
Findings from Kronos Early Estrogen Prevention Study (KEEPS)-Cog trial suggested no cognitive benefit or harm after 48 months of menopausal hormone therapy (mHT) initiated within 3 years of final menstrual period. To clarify the long-term effects of mHT initiated in early postmenopause, the observational KEEPS Continuation Study reevaluated cognition, mood, and neuroimaging effects in participants enrolled in the KEEPS-Cog and its parent study the KEEPS approximately 10 years after trial completion. We hypothesized that women randomized to transdermal estradiol (tE2) during early postmenopause would show cognitive benefits, while oral conjugated equine estrogens (oCEE) would show no effect, compared to placebo over the 10 years following randomization in the KEEPS trial. Methods and findings The KEEPS-Cog (2005–2008) was an ancillary study to the KEEPS ( NCT00154180 ), in which participants were randomized into 3 groups: oCEE (Premarin, 0.45 mg/d), tE2 (Climara, 50 μg/d) both with micronized progesterone (Prometrium, 200 mg/d for 12 d/mo) or placebo pills and patch for 48 months. KEEPS Continuation (2017–2022), an observational, longitudinal cohort study of KEEPS clinical trial, involved recontacting KEEPS participants approximately 10 years after the completion of the 4-year clinical trial to attend in-person research visits. Seven of the original 9 sites participated in the KEEPS Continuation, resulting in 622 women of original 727 being invited to return for a visit, with 299 enrolling across the 7 sites. KEEPS Continuation participants repeated the original KEEPS-Cog test battery which was analyzed using 4 cognitive factor scores and a global cognitive score. Cognitive data from both KEEPS and KEEPS Continuation were available for 275 participants. Latent growth models (LGMs) assessed whether baseline cognition and cognitive changes during KEEPS predicted cognitive performance at follow-up, and whether mHT randomization modified these relationships, adjusting for covariates. Similar health characteristics were observed at KEEPS randomization for KEEPS Continuation participants and nonparticipants (i.e., women not returning for the KEEPS Continuation). The LGM revealed significant associations between intercepts and slopes for cognitive performance across almost all domains, indicating that cognitive factor scores changed over time. Tests assessing the effects of mHT allocation on cognitive slopes during the KEEPS and across all years of follow-up including the KEEPS Continuation visit were all statistically nonsignificant. The KEEPS Continuation study found no long-term cognitive effects of mHT, with baseline cognition and changes during KEEPS being the strongest predictors of later performance. Cross-sectional comparisons confirmed that participants assigned to mHT in KEEPS (oCEE and tE2 groups) performed similarly on cognitive measures to those randomized to placebo, approximately 10 years after completion of the randomized treatments. These findings suggest that mHT poses no long-term cognitive harm; conversely, it provides no cognitive benefit or protective effects against cognitive decline.
Conclusions
In these KEEPS Continuation analyses, there were no long-term cognitive effects of short-term exposure to mHT started in early menopause versus placebo. These data provide reassurance about the long-term neurocognitive safety of mHT for symptom management in healthy, recently postmenopausal women, while also suggesting that mHT does not improve or preserve cognitive function in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Wisconsin, Madison, Wisconsin, United States of America.
- Geriatric Research, Education and Clinical Center (GRECC), William S. Middleton Memorial VA Hospital, Madison, Wisconsin, United States of America.
- Department of Acute & Chronic Care, George Washington University, Washington, DC, United States of America.
- Department of Radiology, Mayo Clinic, Rochester, Minnesota, United States of America.
- Department of Health and Community Systems, University of Pittsburgh School of Nursing, Pittsburgh, Pennsylvania, United States of America.
- Phoenix VA Health Care System, Phoenix, Arizona, United States of America.
ORCID-Profile: Carey E Gleason, N Maritza Dowling, Firat Kara, Taryn T James, Hector Salazar, Sherman M Harman, Michael Malek-Ahmadi
Förderung
- NIA NIH HHS
- NCRR NIH HHS
- NCATS NIH HHS
- National Center for Advancing Translational Sciences
- Brigham Research Institute
- National Institute on Aging
Zitieren
APA
Gleason, C. E., Dowling, N. M., Kara, F., James, T. T., Salazar, H., Ferrer Simo, C. A., Harman, S. M., Manson, J. E., Hammers, D. B., Naftolin, F. N., Pal, L., Miller, V. M., Cedars, M. I., Lobo, R. A., Malek-Ahmadi, M., & Kantarci, K. (2024). Long-term cognitive effects of menopausal hormone therapy: Findings from the KEEPS Continuation Study. PLOS Medicine, 21(11), e1004435. https://doi.org/10.1371/journal.pmed.1004435
Vancouver
Gleason CE, Dowling NM, Kara F, James TT, Salazar H, Ferrer Simo CA, et al. Long-term cognitive effects of menopausal hormone therapy: Findings from the KEEPS Continuation Study. PLOS Medicine. 2024;21(11):e1004435. doi:10.1371/journal.pmed.1004435
BibTeX
@article{Gleason2024,
author = {Gleason, Carey E and Dowling, N Maritza and Kara, Firat and James, Taryn T and Salazar, Hector and Ferrer Simo, Carola A and Harman, Sherman M and Manson, JoAnn E and Hammers, Dustin B and Naftolin, Frederick N and Pal, Lubna and Miller, Virginia M and Cedars, Marcelle I and Lobo, Rogerio A and Malek-Ahmadi, Michael and Kantarci, Kejal},
title = {Long-term cognitive effects of menopausal hormone therapy: Findings from the KEEPS Continuation Study},
journal = {PLOS Medicine},
year = {2024},
volume = {21},
number = {11},
pages = {e1004435},
doi = {10.1371/journal.pmed.1004435}
}
EUVIMED